Global PNH Patient Registry
Part of paid clinical trials in Bethesda, Maryland.
- Sponsor
- Aplastic Anemia and MDS International Foundation
- Study ID
- NCT05755867
- Status
- Recruiting
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The primary aim of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry is to conduct a prospectively-planned and efficient natural history study that will result in a more comprehensive understanding of the disease and its course and pace over time. Other registry objectives include the following: * Provide a convenient online platform for participants (or caregivers) to self-report cases of PNH. * Develop a communications registry within the Global PNH Patient registry (e.g., to notify patients of research studies and clinical trials). * Characterize and describe the Global PNH population as a whole, enhancing the understanding of disease prevalence and phenotype as well as the rate of progression of disease characteristics. * Assist the PNH community with the development of recommendations and standards of care. * Be a case-finding resource to be used for researchers who seek to study the pathophysiology of PNH, retrospectively collate intervention outcomes, and design prospective trials of novel treatments.
Key Dates
- Start date
- May 6, 2021
- Status verified
- Feb 2025
- Primary completion
- May 6, 2026
- Completion
- May 6, 2031
Study Design
- Enrollment
- 500 participants (estimated)
Arms
- Arm: PNH PatientsIndividuals of any age with a confirmed diagnosis of PNH or diagnosis consistent with PNH are eligible for inclusion.
Primary Outcome Measure
Characterize and describe the Global PNH population [ Time Frame: 5-10 years ]
Central Contacts
- Alice Houk, MS3012797202
- Elizabeth Kottke475.289.6855
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Aplastic Anemia and MDS International Foundation | Bethesda | Maryland | 20814 | Alice Houk, MS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Bethesda, MD
Related Studies
- Home Reported Outcomes in PNHRecruiting · Novartis Pharmaceuticals · East Hanover, New Jersey
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.PHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- The International PNH Interest Group PNH RegistryRecruiting · International PNH Interest Group · Altamonte Springs, Florida